Low-Dose Azacitidine, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Clinical Trials Related to Azacitidine
Related studies linked through entity extraction aliases.
Bortezomib and Azacitidine in Treating Patients With Relapsed or Refractory T-Cell Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1
Epigenetic Modulation in Relapsed/Refractory Follicular Lymphoma and Marginal Zone Lymphoma
- Status
- TERMINATED
- Phase
- PHASE2
Azacitidine and Entinostat in Treating Patients With Metastatic Colorectal Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Midostaurin and Azacitidine in Treating Elderly Patients With Acute Myelogenous Leukemia
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Azacitidine in Treating Patients With Relapsed Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Who Have Undergone Stem Cell Transplant
- Status
- COMPLETED
- Phase
- PHASE2
Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML)
- Status
- COMPLETED
- Phase
- PHASE3
Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) in Combination With Azacitidine for the Treatment of Myelodysplastic Syndrome (MDS)
- Status
- COMPLETED
- Phase
- PHASE1
Lenalidomide + Azacitidine for Adaptive Immunotherapy -> Auto SCT in Multiple Myeloma
- Status
- COMPLETED
- Phase
- NA
Evaluation of Azacitidine in Transfusion Dependent Patients With Low-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML)
- Status
- COMPLETED
- Phase
- PHASE2
Azacitidine and Oxaliplatin In Treating Patients With Advanced Cancers Relapsed or Refractory to Any Platinum Therapy
- Status
- COMPLETED
- Phase
- PHASE1
Azacitidine and Lenalidomide for Acute Myeloid Leukemia
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Azacitidine Combined to Epoetin Beta in International Prognostic Scoring System (IPSS) Low-risk and Intermediate-1 Myelodysplastic Syndrome (MDS) Patients, Resistant to Erythropoetin-stimulating Agents (ESA)
- Status
- COMPLETED
- Phase
- PHASE2
To Demonstrate Superiority of Decitabine Over Azacitidine in Subjects With Intermediate- or High-risk MDS.
- Status
- TERMINATED
- Phase
- PHASE4
Vorinostat in Combination With Azacitidine in Patients With Newly-Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)
- Status
- COMPLETED
- Phase
- PHASE2
A Study to Evaluate the Effectiveness of 5-Azacitidine and Bevacizumab in Advanced Renal Cell Carcinoma
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Combination of 5-azacitidine and Lenalidomide in Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML) Myelodysplastic Syndromes
- Status
- TERMINATED
- Phase
- PHASE1
Efficacy of 5-azacytidine Added to Standard Primary Therapy in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
- Status
- COMPLETED
- Phase
- PHASE2
MLN4924 for the Treatment of Acute Myelogenous Leukemia, Myelodysplastic Syndrome, and Acute Lymphoblastic Leukemia
- Status
- COMPLETED
- Phase
- PHASE1
Vorinostat, Azacitidine, and Gemtuzumab Ozogamicin for Older Patients With Relapsed or Refractory AML
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2